SCHEMBL4035833

SCHEMBL4035833

NCCCCN1CCC(F)CC1

nearest known ligand 0.65

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GNAI3 P08754 1/20 0.47
GNAO1 P09471 1/20 0.47
GNAI1 P63096 1/20 0.47
SIGMAR1 Q99720 1/20 0.43
SLC6A4 P31645 1/20 0.41
ALOX15 P16050 1/20 0.40
HRH3 Q9Y5N1 2/20 0.38
CHRM3 P20309 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030838 0.93 KEAP1 (0.58) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
Hydrochloric Acid SCHEMBL29056645 0.91 KEAP1 (0.56) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL855030 0.87 GNAI3 (0.40) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL856513 0.87 GNAI3 (0.40) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL855029 0.87 GNAI3 (0.40) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL508627 0.83 ALOX15 (0.60) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL25031743 0.80 SIGMAR1 (0.50) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL15328845 0.80 KEAP1 (0.43) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL2441151 0.80 KEAP1 (0.43) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1
SCHEMBL2441195 0.80 KEAP1 (0.43) KEAP1SMN1; SMN2GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4644390-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-11-05 EP disclosed
CN-101495465-A 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands GLAXO GROUP LTD (GB) 2009-07-29 CN disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
EP-2021331-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-02-11 EP disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 KEAP1 1984/4885SMN1; SMN2 1002/4885GNAI3 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.